Skip to main content

Table 2 Relative intensities of 13 differential metabolites in serum samples of 6 groups

From: Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat

Differential metabolites

C

M

Y

CL

CM

CH

TG(18:2/18:1/18:2)

1.00 ± 1.01

2.67 ± 0.17**

1.85 ± 0.16

2.64 ± 0.08

1.56 ± 0.08#

1.14 ± 0.17##

TG(20:4/14:0/18:3)

1.00 ± 038

6.08 ± 1.05**

4.86 ± 0.68

5.63 ± 1.23

3.71 ± 1.30

6.39 ± 1.68

PC(24:1/16:1)

1.00 ± 0.32

2.18 ± 0.13**

2.02 ± 0.08

2.11 ± 0.45

1.89 ± 0.11#

2.00 ± 0.04

PC(24:1/18:2)

1.00 ± 0.73

3.78 ± 0.85**

3.59 ± 0.67

1.57 ± 0.34

1.41 ± 0.79##

1.50 ± 0.03#

PC(15:0/18:0)

1.00 ± 0.30

1.48 ± 0.13**

1.39 ± 0.08

1.36 ± 0.09

1.23 ± 0.10#

1.37 ± 0.12

PC(24:1/22:2)

1.00 ± 0.48

2.85 ± 0.52**

0.39 ± 0.09##

0.79 ± 0.33

0.29 ± 0.08##

0.32 ± 0.10##

LPC(16:1/0:0)

1.00 ± 0.62

4.45 ± 2.16**

2.49 ± 1.00

2.49 ± 0.71

2.46 ± 0.80

4.34 ± 2.35

LPC(22:4/0:0)

1.00 ± 0.29

1.96 ± 0.32**

1.53 ± 0.19

1.35 ± 0.11#

1.57 ± 0.38

1.86 ± 0.26

LPC(18:2/0:0)

1.00 ± 0.35

2.11 ± 0.41**

1.56 ± 0.22

1.23 ± 0.19##

1.56 ± 0.43

1.97 ± 0.37

LPC(18:0/0:0)

1.00 ± 0.37

3.59 ± 1.37*

3.24 ± 0.94

2.55 ± 1.09

2.01 ± 1.03

5.02 ± 0.97

PE(18:3/22:4)

1.00 ± 0.30

2.40 ± 0.44**

1.27 ± 0.08

1.34 ± 0.31

1.22 ± 0.29#

1.23 ± 0.42#

PE(24:1/24:1)

1.00 ± 0.32

1.84 ± 0.32*

0.80 ± 0.07

0.86 ± 1.13

0.53 ± 0.08##

0.60 ± 0.12##

CE(24:1)

1.00 ± 0.42

2.11 ± 0.25*

1.11 ± 0.11#

1.43 ± 0.14

0.98 ± 0.57##

1.02 ± 0.11##

  1. The average peak area of potential biomarkers in the control group was set as 1. C, control group; M, model group; Y, benzbromarone group; CL, low dosage group; CM, medium dosage group; CH, high dosage group; ANOVA and nonparametric test were used for statistical analysis, **, p < 0.01 vs. control group. *, p < 0.05 vs. control group; ##, p < 0.01 vs. model group; #, p < 0.05 vs. model group